A discontinuous Galerkin formulation of the Contrast Source Inversion algorithm (DGM-CSI) for microwave breast imaging employing a frequency-cycling reconstruction technique has been modified here to include a set of automated stopping criteria that determine a suitable time to shift imaging frequencies and to globally terminate the reconstruction. Recent studies have explored the use of tissue-dependent geometrical mapping of the well-reconstructed real part to its imaginary part as initial guesses during consecutive frequency hops. This practice was shown to improve resulting 2D images of the dielectric properties of synthetic breast models, but a fixed number of iterations was used to halt DGM-CSI inversions arbitrarily. Herein, a new set of stopping conditions is introduced based on an intelligent statistical analysis of a window of past iterations of data error using the two-sample Kolmogorov-Smirnov (K-S) test. This non-parametric goodness-of-fit test establishes a pattern in the data error distribution, indicating an appropriate time to shift frequencies, or terminate the algorithm. The proposed stopping criteria are shown to improve the efficiency of DGM-CSI while yielding images of equivalent quality to assigning an often liberally overestimated number of iterations per reconstruction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320959 | PMC |
http://dx.doi.org/10.3390/jimaging5050055 | DOI Listing |
Curr Ther Res Clin Exp
December 2024
Department of Critical Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China.
Background: Immunosuppressive agents like cyclosporine have proven effective in some pediatric cases, although there are limited case reports considering potential risks such as secondary infections.
Objective: This study investigated the safety and efficacy of Cyclosporine A in children who did not respond to high-dose corticosteroids combined with intravenous immunoglobulin (IVIG).
Methods: We reported four pediatric patients diagnosed with toxic epidermal necrolysis (TEN) received treatment at our institution.
Ann Hematol
January 2025
Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Collaborative Innovation Center of Hematology, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Peking University, Beijing, China.
Experience using olverembatinib as maintenance therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) after allogeneic hematopoietic cell transplantation (allo-HCT) is limited. We retrospectively collected data from 26 patients with Ph ALL who received only olverembatinib as maintenance therapy after allo-HCT. Olverembatinib was administered as prophylaxis in 18 patients (69.
View Article and Find Full Text PDFCureus
December 2024
Trauma and Orthopaedics, University Hospitals Sussex National Health Service (NHS) Foundation Trust, Sussex, GBR.
Background: The aim of the study is to identify the potential risk factors for postoperative AKI in hip fracture patients.
Design And Methods: Using our local neck of femur (NOF) registration data, patient details were selected using inclusion and exclusion criteria. Electronic records of patients were assessed retrospectively, including blood results, radiological investigations, clinical documentation, and drug charts.
Unlabelled: Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS). Clemastine fumarate, the over-the-counter antihistamine and muscarinic receptor blocker, has remyelinating potential in MS. A clemastine arm was added to an ongoing platform clinical trial TRAP-MS ( NCT03109288 ) to identify a cerebrospinal fluid (CSF) remyelination signature and to collect safety data on clemastine in patients progressing independently of relapse activity (PIRA).
View Article and Find Full Text PDFBMJ Open Qual
January 2025
Department of Pharmacy, Barts Health NHS Trust, London, UK.
Public Health England outlines a national ambition of anticoagulating 90% of eligible patients with atrial fibrillation (AF) by 2029. In 2019/2020, two out of three boroughs reviewed in this study were in the bottom 10% of boroughs compared with others within England. Stroke National Audit data for these three boroughs from 2019 to 2020 identified that in patients with known AF admitted to hospital with strokes, 37% were not anticoagulated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!